Metagenomi (NASDAQ:MGX) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Metagenomi (NASDAQ:MGX - Free Report) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 target price on the stock.

MGX has been the topic of a number of other research reports. Wells Fargo & Company began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an overweight rating and a $25.00 target price on the stock. Jefferies Financial Group began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set a buy rating and a $23.00 target price on the stock. TD Cowen began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an outperform rating on the stock. BMO Capital Markets began coverage on Metagenomi in a research report on Tuesday, March 5th. They issued an outperform rating and a $22.00 price target for the company. Finally, Chardan Capital reaffirmed a buy rating and issued a $21.00 price target on shares of Metagenomi in a research report on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $17.83.

Metagenomi Stock Down 0.2 %

NASDAQ:MGX traded down $0.01 during trading hours on Tuesday, hitting $6.46. The company had a trading volume of 182,344 shares, compared to its average volume of 177,271. The company's 50-day simple moving average is $9.76. Metagenomi has a 52 week low of $5.50 and a 52 week high of $12.74.

Insider Activity at Metagenomi

In other Metagenomi news, major shareholder Holdings A/S Novo purchased 800,000 shares of the company's stock in a transaction on Tuesday, February 13th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $12,000,000.00. Following the purchase, the insider now directly owns 1,739,175 shares of the company's stock, valued at approximately $26,087,625. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.